Nutex Health (NUTX) - 2025 Q3 - Quarterly Results

Filing Information This section provides essential administrative details regarding the Form 8-K filing, including registrant identity and securities information General Information This section provides the foundational details of the Form 8-K filing, including the registrant's identity, jurisdiction, and the date of the report - Registrant: NUTEX HEALTH INC.[2] - Date of Report (Date of earliest event reported): October 20, 2025[2] - State or Other Jurisdiction of Incorporation: Delaware[2] Securities Information This part details the company's registered securities and its status regarding emerging growth company provisions Securities Registered Pursuant to Section 12(b) of the Act | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock, $0.001 par value | NUTX | The NASDAQ Stock Market LLC | - The registrant is not an emerging growth company[4] Current Report Items This section details significant events including preliminary financial results, a Nasdaq delisting notice, and a list of filed exhibits Item 2.02 Results of Operations and Financial Condition Nutex Health Inc. issued a press release on October 20, 2025, providing anticipated preliminary financial metrics for the quarter ended September 30, 2025. This information is furnished, not filed, under SEC regulations - On October 20, 2025, Nutex Health Inc. issued a press release (Exhibit 99.1) containing anticipated preliminary financial metrics for the period ended September 30, 2025[5] - The information furnished in this Item 2.02 and Exhibit 99.1 is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934[6] Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing The Company received a Nasdaq notice of non-compliance due to the late filing of its June 30, 2025 Form 10-Q. Nutex Health submitted a compliance plan and was granted an extension until December 12, 2025, to rectify the filing deficiency - On August 20, 2025, the Company received a notice from Nasdaq for non-compliance with Listing Rule 5250(c)(1) due to the failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025[7] - The Company submitted a plan to Nasdaq on October 15, 2025, to regain compliance and requested an extension until December 12, 2025[8] - Nasdaq granted the extension request on October 16, 2025; failure to file the Form 10-Q by December 12, 2025, will result in a delisting notice[8] Item 9.01 Financial Statements and Exhibits This section lists the exhibits included with the Form 8-K filing, specifically identifying the press release mentioned in Item 2.02 Exhibits | Exhibit No. | Description of Exhibit | | :---------- | :--------------------------- | | 99.1 | Press Release dated October 20, 2025 | Signature This section confirms the official signing and submission of the report by the company's Chief Financial Officer Report Signature The report was officially signed by the Chief Financial Officer of Nutex Health Inc., confirming its submission - The report was signed on behalf of NUTEX HEALTH INC. by Jon C. Bates, Chief Financial Officer[12] - Date of signature: October 20, 2025[12]